MOR 202

Drug Profile

MOR 202

Alternative Names: MOR-03087; MOR202

Latest Information Update: 10 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MorphoSys
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD38 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Preclinical Leukaemia

Most Recent Events

  • 02 Jun 2017 Adverse events and efficacy data from a phase I/IIa trial in Multiple myeloma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 03 Dec 2016 Adverse events and efficacy data from a phase I/IIa trial in Multiple myeloma presented at 58th Annual Meeting and Exposition of the American Society of Hematology
  • 17 Oct 2016 Interim adverse events and efficacy data from a phase I/II trial in Multiple myeloma released by MorphoSys
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top